{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:49:09Z","timestamp":1759333749161,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jaad.2023.02.032","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T20:55:21Z","timestamp":1677531321000},"page":"790-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Caveat mammalian target of rapamycin\u00a0(mTOR) revisited: Neurofibromatosis"],"prefix":"10.1016","volume":"88","author":[{"given":"Warren R.","family":"Heymann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.02.032_bib1","series-title":"Treatment of Skin Disease","first-page":"578","article-title":"Neurofibromatosis, type 1","author":"McLarney","year":"2022"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2023.02.032_bib2","first-page":"i141","article-title":"Quality of life in patients with neurofibromatosis type 1 and 2 in Canada","volume":"2","author":"Hamoy-Jimenez","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"7","key":"10.1016\/j.jaad.2023.02.032_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/ped.14183","article-title":"Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1","volume":"62","author":"Mateos","year":"2020","journal-title":"Pediatr Int"},{"issue":"3","key":"10.1016\/j.jaad.2023.02.032_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/pde.13782","article-title":"Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I","volume":"36","author":"Malhotra","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.02.032_bib5","doi-asserted-by":"crossref","unstructured":"Wataya-Kaneda M, Watanabe Y, Nakamura A, et\u00a0al. Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel. J Am Acad Dermatol. Published online November 2, 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.066","DOI":"10.1016\/j.jaad.2022.08.066"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223003419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223003419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:08:17Z","timestamp":1759273697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223003419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0190962223003419"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.032","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caveat mammalian target of rapamycin\u00a0(mTOR) revisited: Neurofibromatosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}